The Effects of Exercise Versus Inactivity on People With Mitochondrial Muscle Disease
NCT ID: NCT00457314
Last Updated: 2009-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
50 participants
INTERVENTIONAL
2007-06-30
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy
NCT01369901
Magnetic Resonance Imaging (MRI) Muscle Phenotyping in Mitochondrial Disease
NCT02154711
Calf Muscle Strength in Mitochondrial Diseases
NCT02678637
Home-based Training and Supplementation in DM1 Patients
NCT05848830
Oxidative Capacity and Exercise Tolerance in Ambulatory SMA
NCT02895789
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There is no cure yet for mitochondrial myopathies, nor is there any adequate treatment to stall disease progression. Exercise, known to boost the production and function of mitochondria in healthy people, may reduce symptoms in people with mitochondrial myopathies by increasing the number and function of normal mitochondria in an individual muscle cell. The purpose of this study is to determine the effects of exercise training versus inactivity on the expression of normal and mutant mitochondrial DNA and on mitochondrial production within muscle cells in people with mitochondrial myopathies. The study will also assess how cell function, physical endurance, heart function, and quality of life are affected by exercise training and inactivity.
Participants in this 2-year study will first undergo physiological exercise testing, magnetic resonance imaging (MRI) of heart and skeletal muscles, a needle biopsy of muscle, and a questionnaire on quality of life. Participants will then be randomly assigned to partake in regular exercise training or no training for 6 months. After 6 months, all participants will undergo repeat testing of initial evaluations. Participants who had been in the exercising group will then switch to no exercise training for 6 months, and participants who had been in the non-exercising group will switch to regular exercise training for 6 months. The second 6-month period will also be followed by repeat testing of initial evaluations. Participants will then be encouraged to continue exercise training for an additional 1 year, with retesting at the end of the second year. Each of the four evaluations will take about 15 hours over 5 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Participants will partake in regular exercise training for 6 months. After 6 months, they will switch to no exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
Exercise
Regular exercise training
2
Participants will not partake in regular exercise training for 6 months. After 6 months, they will switch to exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
Exercise
Regular exercise training
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise
Regular exercise training
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Single-large scale deletions of mitochondrial DNA
* Point mutations in mitochondrial DNA
Exclusion Criteria
* Symptoms of congestive heart failure; peripheral vascular disease; or lung, kidney, or liver disease
* History of alcohol or substance abuse
* Metal implants or related devices that contraindicate MRI
* Current use of or require any medications that have significant systemic cardiovascular effects
* Diabetes
* Obesity (body mass index \[BMI\] greater than 30)
* Resting systolic blood pressure greater than 140 mmHg and/or diastolic blood pressure greater than 90 mmHg at three different times
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Universit y of Texas Southwestern Medical School
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronald Haller, MD
Role: PRINCIPAL_INVESTIGATOR
University of Texas Southwestern Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.